{'fraction_non_alphanumeric': 0.01436265709156194, 'fraction_numerical': 0.0, 'mean_word_length': 5.340909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The treatment of consumption coagulopathy.

There has been a transformation in our views of consumption coagulopathy in recent years owing to the advances throughout intensive care. The findings about the importance of inhibitors in the coagulation system have resulted in new biochemical understanding. The aim nowadays is to diagnose the early phase of consumption coagulopathy-so-called hypercoagulability. It is possible in this phase to restore the balance by replacement of the inhibitor antithrombin III. This report deals with clinical observations.